Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-World Evaluation of Tislelizumab Treatment Patterns and Effectiveness in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer and Small Cell Lung Cancer

NCT07652736 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT07652736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07652736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-World Evaluation of Tislelizumab Treatment Patterns and Effectiveness in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer and Small Cell Lung Cancer
Lead sponsor
BeOne Medicines
Phase
Observational
Overall status
Recruiting
Start date
June 5, 2026
Completion date
November 17, 2030
Enrollment
440 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer, extensive-stage small cell lung cancer